Bausch + Lomb Corporation (NYSE:BLCO) on Monday announced plans to push two first-in-class ophthalmic pipeline assets into advanced clinical testing following data from recent human trials.
The pipeline programs target dry eye disease and ocular surface pain, representing a combined estimated peak sales potential exceeding $2 billion.
Dry Eye Combination Prepares For Phase 3
The company’s dual-action eye drop combines active ingredients from XIIDRA and MIEBO into a single twice-daily therapy.
In a Phase 2 trial of 443 patients, the candidate missed its Day 29 primary endpoint for superior corneal staining reduction over lifitegrast alone.
